MyMD Pharmaceuticals®’ drug pipeline

MyMD has assembled a compelling portfolio of drug candidates to regulate the immunometabolic response through well-defined and efficient clinical pathways. MYMD-1® has also been shown to be effective in traversing the blood-brain barrier, a differentiator that can increase the drug’s benefit to patients.

MyMD Pharmaceuticals® Drug Candidates

MyMD is using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety and sleep disorders.


23 million Americans* suffer from autoimmune diseases while 80% of older adults have at least one chronic disease, such as heart disease or diabetes. MYMD-1® aims to address these diseases, with anti-aging technology that helps people live healthier, longer lives. It also has been shown to effectively target the immune dysfunction and cytokine storm that leads to death from COVID-19.

Learn More


The opioid epidemic alone cost the US $631 billion from 2015 to 2018*. Supera-CBD has the potential to address the significant unmet need for medications to treat stimulant addictions, specifically cocaine, methamphetamine and opioids, which currently have no approved treatment.

Learn More

Discovering new and better treatments

We’re partnering with Internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. MyMD is working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.

See the Research
  • This field is for validation purposes and should be left unchanged.